Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension.

about

On target to dual block RAS?Molecular modeling, quantum polarized ligand docking and structure-based 3D-QSAR analysis of the imidazole series as dual AT(1) and ET(A) receptor antagonists.

P2860

Q37368669-788A886B-FFDB-43CB-BF93-3A6AEE8E7959 Q39015639-D6349976-2756-4C40-B639-88EE093F6E1A

P2860

Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension.

Item

http://www.wikidata.org/entity/Q36425956

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Targeting angiotensin II type ...... in patients with hypertension.

@ast

Targeting angiotensin II type ...... in patients with hypertension.

@en

type

Item

label

Targeting angiotensin II type ...... in patients with hypertension.

@ast

Targeting angiotensin II type ...... in patients with hypertension.

@en

prefLabel

Targeting angiotensin II type ...... in patients with hypertension.

@ast

Targeting angiotensin II type ...... in patients with hypertension.

@en

P1476

Targeting angiotensin II type ...... in patients with hypertension

@en

P2093

Dimitris P Papadopoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Atrial fibrillation and stroke: four treatment controversies

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

The ONTARGET/TRANSCEND Trial Programme: baseline data.

Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation.

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers.

Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials.

Prevention and treatment of stroke in patients with hypertension.

P304

231-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.10.2.231

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vasilios Papademetriou

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16548772

http://www.w3.org/2001/XMLSchema#string

Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension.

about

P2860

P2860

Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698